ArticleIranian journal of pathology2026
CD155 Expression in Invasive Breast Carcinoma: Association with Immune Tumor Microenvironment.
Article in Iranian journal of pathology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Revisiting the Prognostic Significance of CD155 in Invasive Breast Carcinoma.Iranian journal of pathology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background & Objective: CD155 is as an immune checkpoint molecule that interacts with various activating and inhibitory receptors on T- lymphocytes and natural killer (NK) cells in tumor microenvironment (TME). NK cells and tumor associated macrophages (TAMs) are major components of the immune TME. Methods: 85 cases of invasive breast carcinoma (IBC) were evaluated for immunohistochemical expression of CD155, CD56, and CD163. Results: CD155 was positive in 52.9% of cases, and was significantly associated with larger sized, higher grade, advanced stage tumors, positive lymphovascular invasion (LVI), and aggressive molecular subtypes of IBC. High density of CD56 stained tumor infiltrating NK cells was detected in 30.6% of cases, which was significantly related to larger sized, higher-grade tumors, and aggressive molecular subtypes. High density of stromal TAMs was detected in 55.3% of cases, and was significantly associated with large tumor sizes, higher grade, advanced stage, positive LVI, and aggressive molecular subtypes. CD155 expression was significantly correlated with the densities of NK cells and TAMs in TME. Conclusion: CD155 expression, high density of tumor infiltrating NK cells, and high density of stromal TAMs contribute to progression of IBC. CD155 can play an important immunoregulatory role in the TME.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.